UroGen Pharma Ltd. — Director's Dealing 2019

Jan 29, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2019-01-26

Reporting Person: Schoenberg Mark (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-01-26	Employee Stock Option (right to buy)	$42.50	A	7500	Acquired	2029-01-26	Ordinary Shares (7500)	Direct
2019-01-26	Restricted Stock Unit	$	A	2500	Acquired		Ordinary Shares (2500)	Direct

Footnotes

F1: 33.33% of the shares underlying the stock option will vest on January 26, 2020 and 12.5% of the remaining shares will vest in eight equal quarterly installments thereafter.

F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F3: 33.33% of the RSUs will vest on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal quarterly installments thereafter.